Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SMS995 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SMS995 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * A positive diagnosis of IBS. * Subjects must either have been surgically sterilized, hysterectomized at least 6 months prior to screening, be postmenopausal or be using a double-barrier local * contraception. * Able to communicate well with the investigator, to understand and ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 3 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | - | Undisclosed |
| Johnson & Johnson | JNJ | 1 | - | Anti TNF therapy including infliximab, No Biologics |
| Cooper Companies, Inc. | COO | 1 | N/A | Undisclosed |
SMS995 is an investigational small molecule being developed for Irritable Bowel Syndrome (IBS), a gastrointestinal condition. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
SMS995 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker NVS. The drug is currently in Phase 1 clinical trials for Irritable Bowel Syndrome.
SMS995 is in Phase 1 clinical development. It is an investigational drug for Irritable Bowel Syndrome and has not been approved by the FDA or other regulatory agencies. One Phase 1 trial has been completed.
SMS995 has one completed Phase 1 clinical trial, registered under NCT00584298. The trial, titled 'Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide,' enrolled 50 female participants with Irritable Bowel Syndrome across the United States, Canada, Sweden, and the United Kingdom.
No, SMS995 is not the same as octreotide. The completed Phase 1 trial NCT00584298 used octreotide as a pharmacological modulator to assess colorectal sensation, but SMS995 is the investigational drug being developed for Irritable Bowel Syndrome. The trial was designed to evaluate the feasibility of barostat assessments.